Lonsurf is a medicine used to treat adults with colorectal cancer (cancer of the large bowel) and gastric (stomach) cancer that is metastatic (has spread to other parts of the body). It is used in patients who have already been treated with, or who cannot be given, other treatments for their cancer. It can be used in combination with bevacizumab (another cancer medicine) to treat colorectal cancer. Lonsurf contains the active substances trifluridine and tipiracil.
Therapeutic Indication
### Therapeutic indication **Colorectal cancer** Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents **Gastric cancer** Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Therapeutic Area (MeSH)
ATC Code
L01BC59
ATC Item
trifluridine, combinations
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Lonsurf
Medicine Name
Lonsurf
Aliases
N/ANo risk management plan link.
